Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.

Journal of thrombosis and haemostasis : JTH - 1 Aug 2010

Lin C N, Kao C Y, Miao C H, Hamaguchi N, Wu H L, Shi G Y, Liu Y L, High K A, Lin S W

Abstract excerpt

BACKGROUND: Hemophilia B is an X-linked inherited disorder caused by the lack of functional factor IX (FIX). Currently, treatment of hemophilia B is performed by intravenous infusion of plasma-derived or recombinant FIX. OBJECTIVE: In an effort to reduce factor usage and cost, we investigated the potential use of FIX variants with enhanced specific clotting activity. METHODS: Seven recombinant FIX variants using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Enzyme-Linked Immunosorbent Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor IX

Share to Factor X

Share to Hemophilia B

Share to In Vitro Techniques

Share to Partial Thromboplastin Time

Share to Surface Plasmon Resonance

Source

Identifiers

PMID: 20492477
DOI: 10.1111/j.1538-7836.2010.03913.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.PMID 20492477Read ↗

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.Semantic proximity Read ↗

FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.Semantic proximity Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Coagulation Factor IX for Hemophilia B TherapySemantic proximity Read ↗

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX VariantSemantic proximity Read ↗

Coagulation factor VIII: biological basis of emerging hemophilia A therapiesSemantic proximity Read ↗

Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.Semantic proximity Read ↗

Etranacogene dezaparvovec for hemophilia B gene therapySemantic proximity Read ↗

Gene therapy in an era of emerging treatment options for hemophilia B.Semantic proximity Read ↗

Protein-Engineered Coagulation Factors for Hemophilia Gene TherapySemantic proximity Read ↗

Hemophilia Gene Therapy: Ready for Prime Time?Semantic proximity Read ↗

Factor IX variants improve gene therapy efficacy for hemophilia BSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.